Lead Product(s) : 2-Fluorodeschloroketamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results suggest that there is a superior effect of 2-Fluorodeschloroketamine’s (“2-FDCK”) vs. Ketamine on the depressive-like behavior of the FSL animal model: Both Ketamine and 2-FDCK affected depressive-like symptoms.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 31, 2023
Lead Product(s) : 2-Fluorodeschloroketamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
